Responder and nonresponder patients exhibit different peripheral transcriptional signatures during major depressive episode

Translational Psychiatry

Volumn 2, Issue , 2012, Pages

  Belzeaux, R ^a,b,c   Bergon, A ^b,d   Jeanjean, V ^a,b   Loriod, B ^d   Formisano Treziny C ^e,f   Verrier, L ^b   Loundou, A ^f,g   Baumstarck Barrau, K ^f,g   Boyer, L ^g,h   Gall, V ^d   Gabert, J ^e,f,i   Nguyen, C ^d   Azorin, J M ^b,c   Naudin, J ^b   Ibrahim, E C ^a  

^a University of Mediterranée   (France)

^b HÔPITAL SAINTE MARGUERITE   (France)

^c FondaMental   (France)

^d Aix Marseille university   (France)

^e Aix Marseille University   (France)

^f AIX MARSEILLE UNIVERSITY   (France)

^g TIMONE HOSPITAL   (France)

^h AIX MARSEILLE UNIVERSITY   (France)

ⁱ HÔPITAL NORD   (France)

Author keywords

antidepressant; biomarker; miRNA; mood disorder; PBMC; transcriptome

Indexed keywords

BIOLOGICAL MARKER; INTERFERON REGULATORY FACTOR 2; INTERLEUKIN 1BETA; MESSENGER RNA; MICRORNA; PALMITOYL PROTEIN THIOESTERASE; REACTIVE OXYGEN METABOLITE; SORTILIN; TUMOR NECROSIS FACTOR; ANTIDEPRESSANT AGENT; HISTONE; IL1B PROTEIN, HUMAN; MEMBRANE PROTEIN; PPT1 PROTEIN, HUMAN; TNF PROTEIN, HUMAN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CHROMATIN ASSEMBLY AND DISASSEMBLY; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; HUMAN; LONGITUDINAL STUDY; MAJOR DEPRESSION; MALE; PATHOPHYSIOLOGY; PREDICTION; PREDICTIVE VALUE; PROGNOSIS; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE; CASE CONTROL STUDY; GENETICS; MIDDLE AGED; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; AGED; ANTIDEPRESSIVE AGENTS; CASE-CONTROL STUDIES; DEPRESSIVE DISORDER, MAJOR; FEMALE; GENE EXPRESSION PROFILING; HISTONES; HUMANS; INTERLEUKIN-1BETA; LONGITUDINAL STUDIES; MALE; MEMBRANE PROTEINS; MICRORNAS; MIDDLE AGED; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84869756304     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2012.112     Document Type: Article

References (84)

1. Fekadu A, Wooderson SC, Markopoulo K, Donaldson C, Papadopoulos A, Cleare AJ. What happens to patients with treatment-resistant depression? A systematic review of medium to long term outcome studies. J Affect Disord 2009; 116: 4-11.
2. Kupfer DJ, Frank E, Phillips ML. Major depressive disorder: new clinical, neurobiological, and treatment perspectives. Lancet 2012; 379: 1045-1055.
3. American Psychiatric Association Practice Guideline for the Treatment of Patients with Major Depressive Disorder. 3rd edn. American Psychiatric Association (APA): Arlington, VA, 2010. pp 152.
4. Kennedy SH, Lam RW, Parikh SV, Patten SB, Ravindran AV. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. Introduction. J Affect Disord 2009; 117(Suppl 1): S1-S2.
5. Bauer M, Whybrow PC, Angst J, Versiani M, Moller HJ. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and continuation treatment of major depressive disorder. World J Biol Psychiatry 2002; 3: 5-43.
6. Frank E, Prien RF, Jarrett RB, Keller MB, Kupfer DJ, Lavori PW et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 1991; 48: 851-855.
7. Seemuller F, Riedel M, Obermeier M, Bauer M, Adli M, Kronmuller K et al. Outcomes of 1014 naturalistically treated inpatients with major depressive episode. Eur Neuropsychopharmacol 2010; 20: 346-355.
8. Trivedi MH, Fava M, Wisniewski SR, Thase ME, Quitkin F, Warden D et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med 2006; 354: 1243-1252.
9. Uher R, Mors O, Rietschel M, Rajewska-Rager A, Petrovic A, Zobel A et al. Early and delayed onset of response to antidepressants in individual trajectories of change during treatment of major depression: a secondary analysis of data from the Genome- Based Therapeutic Drugs for Depression (GENDEP) study. J Clin Psychiatry 2011; 72: 1478-1484.
10. Tadic A, Wagner S, Gorbulev S, Dahmen N, Hiemke C, Braus DF et al. Peripheral blood and neuropsychological markers for the onset of action of antidepressant drugs in patients with Major Depressive Disorder. BMC Psychiatry 2011; 11: 16.
11. Heim C, Binder EB. Current research trends in early life stress and depression: review of human studies on sensitive periods, gene-environment interactions, and epigenetics. Exp Neurol 2012; 233: 102-111.
12. Sun H, Kennedy PJ, Nestler EJ. Epigenetics of the Depressed Brain: Role of Histone Acetylation and Methylation. Neuropsychopharmacology 2012; e pub ahead of print 14 June 2012. doi:10.1038/npp.2012.73.
13. Belzeaux R, Formisano-Treziny C, Loundou A, Boyer L, Gabert J, Samuelian JC et al. Clinical variations modulate patterns of gene expression and define blood biomarkers in major depression. J Psychiatr Res 2010; 44: 1205-1213.
14. Mehta D, Menke A, Binder EB. Gene expression studies in major depression. Curr Psychiatry Rep 2010; 12: 135-144.
15. Woelk CH, Singhania A, Perez-Santiago J, Glatt SJ, Tsuang MT. The utility of gene expression in blood cells for diagnosing neuropsychiatric disorders. Int Rev Neurobiol 2011; 101: 41-63.
16. Liew CC, Ma J, Tang HC, Zheng R, Dempsey AA. The peripheral blood transcriptome dynamically reflects system wide biology: a potential diagnostic tool. J Lab Clin Med 2006; 147: 126-132. (Pubitemid 43288168)
17. Jasinska AJ, Service S, Choi OW, DeYoung J, Grujic O, Kong SY et al. Identification of brain transcriptional variation reproduced in peripheral blood: an approach for mapping brain expression traits. Hum Mol Genet 2009; 18: 4415-4427.
18. Le-Niculescu H, Kurian SM, Yehyawi N, Dike C, Patel SD, Edenberg HJ et al. Identifying blood biomarkers for mood disorders using convergent functional genomics. Mol Psychiatry 2009; 14: 156-174.
19. Mamdani F, Berlim MT, Beaulieu M-M, Labbe A, Merette C, Turecki G. Gene expression biomarkers of response to citalopram treatment in major depressive disorder. Transl Psychiatry 2011; 1: e13.
20. Lee BH, Kim YK. BDNF mRNA expression of peripheral blood mononuclear cells was decreased in depressive patients who had or had not recently attempted suicide. J Affect Disord 2010; 125: 369-373.
21. Yi Z, Li Z, Yu S, Yuan C, Hong W, Wang Z et al. Blood-based gene expression profiles models for classification of subsyndromal symptomatic depression and major depressive disorder. PLoS One 2012; 7: e31283.
22. Spijker S, Van Zanten JS, De Jong S, Penninx BW, van Dyck R, Zitman FG et al. Stimulated gene expression profiles as a blood marker of major depressive disorder. Biol Psychiatry 2010; 68: 179-186.
23. Pajer K, Andrus BM, Gardner W, Lourie A, Strange B, Campo J et al. Discovery of blood transcriptomics markers for depression in animal models and pilot validation in subjects with early-onset major depression. Transl Psychiatry 2012; 2: e101.
24. Galecki P, Galecka E, Maes M, Chamielec M, Orzechowska A, Bobinska K et al. The expression of genes encoding for COX-2, MPO, iNOS, and sPLA2-IIA in patients with recurrent depressive disorder. J Affect Disord 2012; 138: 360-366.
25. Zhang J, Chen Y, Zhang K, Yang H, Sun Y, Fang Y et al. A cis-phase interaction study of genetic variants within the MAOA gene in major depressive disorder. Biol Psychiatry 2010; 68: 795-800.
26. Numata S, Iga J, Nakataki M, Tayoshi S, Taniguchi K, Sumitani S et al. Gene expression and association analyses of the phosphodiesterase 4B (PDE4B) gene in major depressive disorder in the Japanese population. Am J Med Genet B Neuropsychiatr Genet 2009; 150B: 527-534.
27. Cattaneo A, Bocchio-Chiavetto L, Zanardini R, Milanesi E, Placentino A, Gennarelli M. Reduced peripheral brain-derived neurotrophic factor mRNA levels are normalized by antidepressant treatment. Int J Neuropsychopharmacol 2010; 13: 103-108.
28. Cattaneo A, Sesta A, Calabrese F, Nielsen G, Riva MA, Gennarelli M. The expression of VGF is reduced in leukocytes of depressed patients and it is restored by effective antidepressant treatment. Neuropsychopharmacology 2010; 35: 1423-1428.
29. Abe N, Uchida S, Otsuki K, Hobara T, Yamagata H, Higuchi F et al. Altered sirtuin deacetylase gene expression in patients with a mood disorder. J Psychiatr Res 2011; 45: 1106-1112.
30. Higuchi F, Uchida S, Yamagata H, Otsuki K, Hobara T, Abe N et al. State-dependent changes in the expression of DNA methyltransferases in mood disorder patients. J Psychiatr Res 2011; 45: 1295-1300.
31. Nakataki M, Iga J, Numata S, Yoshimoto E, Kodera K, Watanabe SY et al. Gene expression and association analysis of the epithelial membrane protein 1 gene in major depressive disorder in the Japanese population. Neurosci Lett 2011; 489: 126-130.
32. Eady JJ, Wortley GM, Wormstone YM, Hughes JC, Astley SB, Foxall RJ et al. Variation in gene expression profiles of peripheral blood mononuclear cells from healthy volunteers. Physiol Genomics 2005; 22: 402-411. (Pubitemid 41356372)
33. Fiori LM, Turecki G. Broadening our horizons: gene expression profiling to help better understand the neurobiology of suicide and depression. Neurobiol Dis 2012; 45: 14-22.
34. Im HI, Kenny PJ. MicroRNAs in neuronal function and dysfunction. Trends Neurosci 2012; 35: 325-334.
35. O'Connor RM, Dinan TG, Cryan JF. Little things on which happiness depends: microRNAs as novel therapeutic targets for the treatment of anxiety and depression. Mol Psychiatry 2012; 17: 359-376.
36. Smalheiser NR, Lugli G, Rizavi HS, Torvik VI, Turecki G, Dwivedi Y. MicroRNA expression is down-regulated and reorganized in prefrontal cortex of depressed suicide subjects. PLoS One 2012; 7: e33201.
37. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR). American Psychiatric Association: Arlington, VA, 2000. 38.
38. American Psychiatric Association Handbook of Psychiatric Measures. 2nd edn. American Psychiatric Association (APA): Washington, DC, 2008. pp 864.
39. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009; 4: 44-57.
40. Chen J, Bardes EE, Aronow BJ, Jegga AG. ToppGene Suite for gene list enrichment analysis and candidate gene prioritization. Nucleic Acids Res 2009; 37: W305-W311.
41. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001; 98: 5116-5121. (Pubitemid 32397092)
42. Saeed AI, Bhagabati NK, Braisted JC, Liang W, Sharov V, Howe EA et al. TM4 microarray software suite. Methods Enzymol 2006; 411: 134-193.
43. Shelton RC, Claiborne J, Sidoryk-Wegrzynowicz M, Reddy R, Aschner M, Lewis DA et al. Altered expression of genes involved in inflammation and apoptosis in frontal cortex in major depression. Mol Psychiatry 2011; 16: 751-762.
44. Drexhage RC, van der Heul-Nieuwenhuijsen L, Padmos RC, van Beveren N, Cohen D, Versnel MA et al. Inflammatory gene expression in monocytes of patients with schizophrenia: overlap and difference with bipolar disorder. A study in naturalistically treated patients. Int J Neuropsychopharmacol 2010; 13: 1369-1381.
45. Duric V, Banasr M, Stockmeier CA, Simen AA, Newton SS, Overholser JC et al. Altered expression of synapse and glutamate related genes in post-mortem hippocampus of depressed subjects. Int J Neuropsychopharmacol 2012; e-pub ahead of print 22 February 2012; doi:10.017/S1461145712000016.
46. Guilloux JP, Douillard-Guilloux G, Kota R, Wang X, Gardier AM, Martinowich K et al. Molecular evidence for BDNF- and GABA-related dysfunctions in the amygdala of female subjects with major depression. Mol Psychiatry 2011; e-pub ahead of print 14 September 2011; doi:10.038/mp.2011.113.
47. Duric V, Banasr M, Licznerski P, Schmidt HD, Stockmeier CA, Simen AA et al. A negative regulator of MAP kinase causes depressive behavior. Nat Med 2010; 16: 1328-1332.
48. Bernard R, Kerman IA, Thompson RC, Jones EG, Bunney WE, Barchas JD et al. Altered expression of glutamate signaling, growth factor, and glia genes in the locus coeruleus of patients with major depression. Mol Psychiatry 2011; 16: 634-646.
49. Sibille E, Wang Y, Joeyen-Waldorf J, Gaiteri C, Surget A, Oh S et al. A molecular signature of depression in the amygdala. Am J Psychiatry 2009; 166: 1011-1024.
50. Sequeira A, Mamdani F, Ernst C, Vawter MP, Bunney WE, Lebel V et al. Global brain gene expression analysis links glutamatergic and GABAergic alterations to suicide and major depression. PLoS One 2009; 4: e6585.
51. Klempan TA, Sequeira A, Canetti L, Lalovic A, Ernst C, Affrench-Mullen J et al. Altered expression of genes involved in ATP biosynthesis and GABAergic neurotransmission in the ventral prefrontal cortex of suicides with and without major depression. Mol Psychiatry 2009; 14: 175-189.
52. Chu TT, Liu Y, Kemether E. Thalamic transcriptome screening in three psychiatric states. J Hum Genet 2009; 54: 665-675.
53. Tochigi M, Iwamoto K, Bundo M, Sasaki T, Kato N, Kato T. Gene expression profiling of major depression and suicide in the prefrontal cortex of postmortem brains. Neurosci Res 2008; 60: 184-191.
54. Kang HJ, Adams DH, Simen A, Simen BB, Rajkowska G, Stockmeier CA et al. Gene expression profiling in postmortem prefrontal cortex of major depressive disorder. J Neurosci 2007; 27: 13329-13340. (Pubitemid 350220503)
55. Sequeira A, Klempan T, Canetti L, Affrench-Mullen J, Benkelfat C, Rouleau GA et al. Patterns of gene expression in the limbic system of suicides with and without major depression. Mol Psychiatry 2007; 12: 640-655. (Pubitemid 46998251)
56. Sequeira A, Gwadry FG, Ffrench-Mullen JM, Canetti L, Gingras Y, Casero RA Jr et al. Implication of SSAT by gene expression and genetic variation in suicide and major depression. Arch Gen Psychiatry 2006; 63: 35-48. (Pubitemid 43037467)
57. Choudary PV, Molnar M, Evans SJ, Tomita H, Li JZ, Vawter MP et al. Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression. Proc Natl Acad Sci USA 2005; 102: 15653-15658. (Pubitemid 41528111)
58. Aston C, Jiang L, Sokolov BP. Transcriptional profiling reveals evidence for signaling and oligodendroglial abnormalities in the temporal cortex from patients with major depressive disorder. Mol Psychiatry 2005; 10: 309-322. (Pubitemid 40432684)
59. Iwamoto K, Kakiuchi C, Bundo M, Ikeda K, Kato T. Molecular characterization of bipolar disorder by comparing gene expression profiles of postmortem brains of major mental disorders. Mol Psychiatry 2004; 9: 406-416. (Pubitemid 38534701)
60. Evans SJ, Choudary PV, Neal CR, Li JZ, Vawter MP, Tomita H et al. Dysregulation of the fibroblast growth factor system in major depression. Proc Natl Acad Sci USA 2004; 101: 15506-15511. (Pubitemid 39441571)
61. Sibille E, Arango V, Galfalvy HC, Pavlidis P, Erraji-Benchekroun L, Ellis SP et al. Gene expression profiling of depression and suicide in human prefrontal cortex. Neuropsychopharmacology 2004; 29: 351-361. (Pubitemid 38175153)
62. Segman RH, Goltser-Dubner T, Weiner I, Canetti L, Galili-Weisstub E, Milwidsky A et al. Blood mononuclear cell gene expression signature of postpartum depression. Mol Psychiatry 2010; 15: 93-100.
63. Raison CL, Miller AH. Is depression an inflammatory disorder? Curr Psychiatry Rep 2011; 13: 467-475.
64. Lai CY, Yu SL, Hsieh MH, Chen CH, Chen HY, Wen CC et al. MicroRNA expression aberration as potential peripheral blood biomarkers for schizophrenia. PLoS One 2011; 6: e21635.
65. Shi W, Du J, Qi Y, Liang G, Wang T, Li S et al. Aberrant expression of serum miRNAs in schizophrenia. J Psychiatr Res 2012; 46: 198-204.
66. Gardiner E, Beveridge NJ, Wu JQ, Carr V, Scott RJ, Tooney PA et al. Imprinted DLK1- DIO3 region of 14q32 defines a schizophrenia-associated miRNA signature in peripheral blood mononuclear cells. Mol Psychiatry 17: 827-840.
67. Santarelli DM, Beveridge NJ, Tooney PA, Cairns MJ. Upregulation of dicer and microRNA expression in the dorsolateral prefrontal cortex Brodmann area 46 in schizophrenia. Biol Psychiatry 2011; 69: 180-187.
68. Miller BH, Zeier Z, Xi L, Lanz TA, Deng S, Strathmann J et al. MicroRNA-132 dysregulation in schizophrenia has implications for both neurodevelopment and adult brain function. Proc Natl Acad Sci USA 2012; 109: 3125-3130.
69. Kim AH, Reimers M, Maher B, Williamson V, McMichael O, McClay JL et al. MicroRNA expression profiling in the prefrontal cortex of individuals affected with schizophrenia and bipolar disorders. Schizophr Res 2010; 124: 183-191.
70. Beveridge NJ, Gardiner E, Carroll AP, Tooney PA, Cairns MJ. Schizophrenia is associated with an increase in cortical microRNA biogenesis. Mol Psychiatry 2010; 15: 1176-1189.
71. Perkins DO, Jeffries CD, Jarskog LF, Thomson JM, Woods K, Newman MA et al. microRNA expression in the prefrontal cortex of individuals with schizophrenia and schizoaffective disorder. Genome Biol 2007; 8: R27.
72. Khalil AM, Guttman M, Huarte M, Garber M, Raj A, Rivea Morales D et al. Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. Proc Natl Acad Sci USA 2009; 106: 11667-11672.
73. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008; 9: 46-56. (Pubitemid 350295688)
74. Padmos RC, Hillegers MH, Knijff EM, Vonk R, Bouvy A, Staal FJ et al. A discriminating messenger RNA signature for bipolar disorder formed by an aberrant expression of inflammatory genes in monocytes. Arch Gen Psychiatry 2008; 65: 395-407. (Pubitemid 351519889)
75. Shao L, Vawter MP. Shared gene expression alterations in schizophrenia and bipolar disorder. Biol Psychiatry 2008; 64: 89-97.
76. Ryan MM, Lockstone HE, Huffaker SJ, Wayland MT, Webster MJ, Bahn S. Gene expression analysis of bipolar disorder reveals downregulation of the ubiquitin cycle and alterations in synaptic genes. Mol Psychiatry 2006; 11: 965-978. (Pubitemid 44470218)
77. Kao CF, Jia P, Zhao Z, Kuo PH. Enriched pathways for major depressive disorder identified from a genome-wide association study. Int J Neuropsychopharmacol 2012; 15: 1401-1411.
78. Janssen DG, Caniato RN, Verster JC, Baune BT. A psychoneuroimmunological review on cytokines involved in antidepressant treatment response. Hum Psychopharmacol 2010; 25: 201-215.
79. Bufalino C, Hepgul N, Aguglia E, Pariante CM. The role of immune genes in the association between depression and inflammation: A review of recent clinical studies. Brain Behav Immun 2012; e-pub ahead of print 15 May 2012; doi:10.016/j.bbi.2012.04.009.
80. Warner-Schmidt JL, Vanover KE, Chen EY, Marshall JJ, Greengard P. Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by antiinflammatory drugs in mice and humans. Proc Natl Acad Sci USA 2011; 108: 9262-9267.
81. Hobara T, Uchida S, Otsuki K, Matsubara T, Funato H, Matsuo K et al. Altered gene expression of histone deacetylases in mood disorder patients. J Psychiatr Res 2010; 44: 263-270.
82. Happel N, Doenecke D. Histone H1 and its isoforms: contribution to chromatin structure and function. Gene 2009; 431: 1-12.
83. Saja S, Buff H, Smith AC, Williams TS, Korey CA. Identifying cellular pathways modulated by Drosophila palmitoyl-protein thioesterase 1 function. Neurobiol Dis 2010; 40: 135-145.
84. Leuchter AF, Cook IA, Hamilton SP, Narr KL, Toga A, Hunter AM et al. Biomarkers to predict antidepressant response. Curr Psychiatry Rep 2010; 12: 553-562.